TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A liver biopsy within 3 years prior to the screening visit (or between screening and day of randomization) with histology consistent with chronic Hepatitis C virus (HCV) infection~* Presence of contraindications for a liver biopsy in patients who are otherwise deemed eligible for participation does not exclude the patient from participation~* Genotype 1 HCV infection (confirmed at screening)~* Plasma HCV RNA of \> 10,000 IU/mL at screening~Exclusion Criteria:~* Prior treatment with any approved or investigational drug for the treatment of hepatitis C~* Co-infection with hepatitis B virus or human immunodeficiency virus (HIV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- TMC435 150 mg (Type: EXPERIMENTAL): Patients will receive 12 weeks TMC435 150 mg once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV), followed by PegIFNα-2a and RBV alone. Response-guided treatment criteria will be used to determine total treatment duration of 24 or 48 weeks for patients in the TMC435 treatment groups. Patients in the control group will continue to receive treatment with PegIFNα-2a and RBV until Week 48.
- TMC435 100 mg (Type: EXPERIMENTAL): Patients will receive 12 weeks TMC435 100 mg once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV), followed by PegIFNα-2a and RBV alone. Response-guided treatment criteria will be used to determine total treatment duration of 24 or 48 weeks for patients in the TMC435 treatment groups. Patients in the control group will continue PegIFNα-2a and RBV until Week 48.
- Control (Type: PLACEBO_COMPARATOR): Patients will receive placebo once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV) for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Tolerance Clinical Study on Aerosol Inhalation of Mesenchymal Stem Cells Exosomes In Healthy Volunteers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy volunteers.~2. Age: 19-45, males and females.~3. The weight is within ± 10% of the standard weight \[standard weight (kg) = 0.7 × (height cm-80)\].~4. Examination indices of heart, liver, kidney and blood are all within the normal range.~5. According to Good Clinical Practice (GCP), volunteers who understand and voluntarily sign the consent form before this study.~Exclusion Criteria:~1. Women in pregnancy or lactation.~2. Primary diseases of important organs.~3. Mentally or physically disabled patients.~4. Suspected or definite history of alcohol and drug abuse.~5. According to the investigator's judgment, there is a low possibility of enrollment (such as frailty, etc.).~6. Volunteers who are allergic to the components of this medicine, or have a history of allergies to two or more drugs or food.~7. Volunteers who have diseases (such as insomnia) and are using other preventive and therapeutic drugs before this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1X level (Type: EXPERIMENTAL): Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (2.0\*10\^8 nano vesicles/3 ml)
- 2X level (Type: EXPERIMENTAL): Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (4.0\*10\^8 nano vesicles/3 ml)
- 4X level (Type: EXPERIMENTAL): Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (8.0\*10\^8 nano vesicles/3 ml)
- 6X level (Type: EXPERIMENTAL): Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (12.0\*10\^8 nano vesicles/3 ml)
- 8X level (Type: EXPERIMENTAL): Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (16.0\*10\^8 nano vesicles/3 ml)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of S. Boulardii and Amoxicillin/Clavulanate on Gut Microbiota

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 65 years (male or female)~* Good general health~* Able to comply with study requirements and to provide informed consent~* For women of childbearing potential oA negative urine pregnancy test immediately prior to starting the study treatment oAgreement to comply with approved methods of contraception during the period of active study treatment (not required during follow-up)~Exclusion Criteria:~* History of organ transplantation~* Known chronic or recurrent systemic disorder associated with immunocompromise~* A history of allergy or hypersensitivity to Saccharomyces boulardii, brewer's or baker's yeast, amoxicillin, penicillins, or cephalosporins~* History of severe allergic reaction (requiring hospital admission and/or the administration of parenteral medication or associated with dyspnoea, wheezing, hypotension, loss of consciousness).~* Oral or systemic antibacterial therapy during the 3 months prior to study enrollment~* New prescription medications during the 4 weeks prior to study enrollment~* Prescription, OTC medications or supplements that are known to alter gut function or microflora (i.e. acid antisecretory drugs, probiotics) during the 4 weeks prior to study enrollment~* Active gastrointestinal disease~* Patients with a central venous catheter~* Patients taking antifungals or laxatives within 14 days of enrolment~* Patients enrolled in other clinical trials within the past 60 days~* Prior gastrointestinal surgery (apart from appendectomy or cholecystectomy)~* History of chronic constipation with passage of fewer than 3 bowel movements per week on average~* Any condition or personal circumstance that, in the opinion of the investigator, renders the subject unlikely or unable to comply with the full study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- prebiotic (Saccharomyces boulardii) (Type: ACTIVE_COMPARATOR): 500 mg, 2 times daily for 14 days
- antibiotic (Amoxicillin Clavulanate) (Type: ACTIVE_COMPARATOR): 875/125 mg 2 times daily at least 1 hour before meals for 7 days
- combination (prebiotic and antibiotic) (Type: ACTIVE_COMPARATOR): Amoxicillin Clavulanate for 7 days (days 1 to 7; 875/125 mg 2 times daily at least 1 hour before meals) in addition to the dietary supplement Saccharomyces boulardii for 14 days (days 1 to 14; 500 mg, 2 times daily).
- control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Active ulcerative proctitis~* Diagnosis confirmed by endoscopy~* Established disease or new diagnosis~Exclusion Criteria:~* Crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis, diverticular assoc. colitis, microscopic colitis~* Presence of proctitis of a different origin~* Prior bowel resection~* Presence of symptomatic organic disease of the gastrointestinal tract~* Asthma, tuberculosis, cardiovascular disease, diabetes mellitus, osteoporosis, active peptic ulcer disease, glaucoma, cataract, infection if careful medical monitoring is not ensured~* Local intestinal infection~* Abnormal hepatic or renal function~* Oral/rectal/intravenous corticosteroids therapy~* Existing or intended pregnancy or breast-feeding~* Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Budesonide dosage 1 (Type: EXPERIMENTAL): Budesonide 2 mg suppository
- Budesonide dosage 2 (Type: EXPERIMENTAL): Budesonide 4 mg suppository
- Mesalazine (Type: ACTIVE_COMPARATOR): Mesalazine 1g suppository
- Combination (Type: EXPERIMENTAL): Budesonide 2 mg suppository/Mesalazine 1 g suppository

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Pacemaker With Closed Loop Stimulation Compared to Pacemakers With and Without Standard Rate Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Implanted within the last 45 days or being considered for implant with a BIOTRONIK pacemaker utilizing CLS rate adaptation technology (currently the Cylos family of pacemakers).~* Ability to give written informed consent~* Geographically stable and able to return for regular follow-ups for 12 months after ADL testing~* At least 18 years old~Exclusion Criteria:~* Patients physically limited and unable to perform all or parts of the ADL testing~* Currently enrolled in any other clinical study~* Patients with medical reasons that preclude regular participation in the follow-ups

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Closed Loop Stimulation (CLS) (Type: ACTIVE_COMPARATOR): Pacemaker programmed with Closed Loop Stimulation rate adaptive technology for long-term follow-up data collection.
- Standard Rate Adaptive Technology (R) (Type: ACTIVE_COMPARATOR): Pacemaker programmed with standard rate adaptive technology (R, accelerometer) for long-term follow-up data collection.
- Non-rate adaptive pacing (DDD) (Type: ACTIVE_COMPARATOR): Pacemaker programmed with no rate adaption (DDD mode) for long-term follow-up data collection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Low Concentration Atropine on Pupillary Size and Accommodative Amplitude

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Able to read and comprehend Vietnamese and having parents or legal guardians who give informed consent as demonstrated by signing a record of informed consent.~* Be between 6 and 12 years old, male or female.~* Willing to apply eye drops once nightly at bedtime for two weeks and follow the clinical trial visit schedule as directed by the Investigator.~* Willing to answer the questionnaire about subjective measurements~* Have ocular findings deemed to be normal~* No contact lens wearing history~* Vision correctable to at least 20/25 or better in each eye with spectacles~Exclusion Criteria:~* Any pre-existing ocular irritation, injury or condition, including infection or disease.~* Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto-immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants.~* Use of or a need for concurrent category S3 and above ocular medication at enrolment and/or during the clinical trial.~* Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant's ocular health / physiology or contact lens performance either in an adverse or beneficial manner at enrolment and/or during the clinical trial.~NB: Systemic antihistamines are allowed on an as needed basis, provided they are not used prophylactically during the trial and at least 24 hours before the clinical trial product is used.~* History of eye surgery~* History of use of any myopia control interventions such as Orthokeratology, Rigid Permeable Contact Lenses Eye surgery within 12 weeks immediately prior to enrolment for this trial.~* Currently treated with other interventions for myopia control~* Contraindications to atropine such as pulmonary disease, heart conditions and ADHD~* Known allergy or intolerance to ingredients to atropine eye-drops and other derivatives of anti-muscarinic receptor agents.~* Currently enrolled in another clinical trial.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- 0.01% atropine eye drops (Type: ACTIVE_COMPARATOR): Participants will receive one drop per eye every night for two weeks
- 0.02% atropine eye drops (Type: ACTIVE_COMPARATOR): Participants will receive one drop per eye every night for two weeks
- 0.03% atropine eye drops (Type: ACTIVE_COMPARATOR): Participants will receive one drop per eye every night for two weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intra-articular Injection in the Knee of Adipose Derived Stromal Cells and Platelet Rich Plasma for Osteoarthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients age 50 or older who present with symptomatic primary osteoarthritis of the knee~* daily pain for the previous 3 months~* analgesics usage at least once a week~* less than 30 minutes of morning stiffness~* WOMAC score of ≤ 75 in the target knee~* Brandt Radiographic Grading Scale of Osteoarthritis grade 1 and 2~Exclusion Criteria:~* evidence of secondary knee osteoarthritis~* severe osteoarthritis (Joint space width - JSW \< 2 mm)~* prior intra articular injections within the previous one year prior to inclusion~* patients with clinically significant systemic disease

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SVF and PRP (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin Added-on to Insulin Study (0431-051)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has type 2 diabetes mellitus~* Patient is poorly controlled while on insulin or insulin and metformin~Exclusion Criteria:~* Patient has a history of type 1 diabetes mellitus or history of ketoacidosis~* Patient is taking oral antidiabetic agents other than metformin during the past 3 months~* Patient is currently on treatment with daily use of pre-prandial short-acting or rapid-acting insulin

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): sitagliptin
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 12 years of age or older in good general health~* Investigator's Static Global Assessment (ISGA) score of 2 or greater at Baseline~Exclusion Criteria:~* Any nodulo-cystic lesions at Baseline~* Pregnancy or breast feeding~* History or presence of regional enteritis or inflammatory bowel disease or similar symptoms.~* Treatment with estrogens, including oral, implanted and topical contraceptives, androgens, or anti-androgenic agents for 12 weeks or less prior to study start.~* Use of topical anti-acne medications within the past 2 weeks.~* Use of topical or systemic antibiotics on the face within the past 2 weeks.~* Use of topical or systemic corticosteroids within the past 2 weeks.~* Use of systemic retinoids within the past 3 months.~* Use of astringents, toners and skin cleansers for less than 2 weeks prior to the start of the study.~* Concomitant use of facial product containing glycolic or other acids, masks, washes or soaps containing benzoyl peroxide or salicylic acid, non mild cleansers or moisturizers containing retinol, salicylic or α- or β-hydroxy acids.~* Concomitant use of mega-doses of certain vitamins, such as vitamin D (\>2000IU QD) vitamin B12, haloperidol, halogens such as iodide and bromide, lithium, hydantoin and phenobarbital.~* Facial procedures (chemical or laser peel, microdermabrasion, etc.) within the past 2 weeks or during the study.~* Concomitant use of tanning booths or sunbathing.~* Known hypersensitivity or previous allergic reaction to any of the active components, lincomycin, retinoids or excipients of the study product~* A significant medical history of or are currently immunocompromised~* Current drug or alcohol abuse. (Drug screening not required.)~* Use of any investigational therapy within 4 weeks of enrollment.~* Any other condition which, in the judgment of the investigator, would put the subject at unacceptable risk for participation in the study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): CT Gel
- 2 (Type: ACTIVE_COMPARATOR): Clindamycin Gel (clindamycin)
- 3 (Type: ACTIVE_COMPARATOR): Tretinoin Gel (tretinoin)
- 4 (Type: PLACEBO_COMPARATOR): Vehicle Gel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Latanoprost on Choroidal Blood Flow Regulation in Human Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men aged between 19 and 35 years, nonsmokers~* Body mass index between 15th and 85th percentile (Must et al. 1991)~* Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant~* Normal ophthalmic findings, ametropia \< 3 dpt.~Exclusion Criteria:~* Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study~* Treatment in the previous 3 weeks with any drug~* Symptoms of a clinically relevant illness in the 3 weeks before the first study day~* History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with distribution, metabolism or excretion of study drugs~* Blood donation during the previous 3 weeks~* Ametropia \>= 3 dpt~* Iris bicolor

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Latanoprost 0.005%, Xalatan®
- 2 (Type: PLACEBO_COMPARATOR): Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mifepristone Plus Misoprostol Versus Misoprostol Alone for 2nd Trimester Abortion (14 - 21 Weeks Last Menstrual Period (LMP))

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 14 to 21 weeks gestation, based on menstrual history and clinical exam (with or without ultrasound)~* Meet legal criteria to obtain abortion~* Present with closed cervical os and no vaginal bleeding~* Live fetus at time of presentation for service~* Have no contraindications to study procedures, according to provider~* Be able to consent to procedure, either by reading consent document or by having consent document read to her~* Be willing to follow study procedures~Exclusion Criteria:~* Known previous transmural uterine incision~* Known allergy to mifepristone or misoprostol/prostaglandin or other contraindications to the use of mifepristone or misoprostol~* Any contraindications to vaginal delivery, including placenta previa~* Presentation in active labor (defined as moderate to severe contractions every 10 minutes or less)

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- mifepristone+misoprostol (Type: EXPERIMENTAL): 200 mg mifepristone followed by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 10 doses within 48 hours (maximum 5 doses per 24 hours).
- misoprostol (Type: ACTIVE_COMPARATOR): Placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion up to a maximum of 10 doses within 48 hours (maximum 5 doses per 24 hours).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete